Methyl-CpG-binding domain protein 3 (MBD3)

Methyl-CpG-binding domain protein 3 (MBD3) is a nuclear protein encoded by the human MBD3 gene and a member of the methyl-CpG binding domain family, which recognizes DNA methylation and mediates chromatin remodeling and transcriptional regulation through its function as a core subunit of the NuRD (Nucleosome Remodeling and Deacetylase) complex. Unlike other MBD proteins, MBD3 preferentially binds hydroxymethylated and unmethylated CpG DNA regions rather than methylated DNA, positioning it as a unique regulator of epigenetically “active” promoters. MBD3 influences diverse biological processes including gene expression, chromatin structure, embryonic development, and DNA methylation homeostasis. It plays an important role in cancer biology, modulating tumor proliferation, metastasis, immune evasion, and gene silencing. As a component of the NuRD complex, MBD3 interacts with proteins such as AURKA, GATAD2B, HDAC1, MTA2, and MBD2. Targeting MBD3 and related epigenetic regulators is an area of active therapeutic investigation, though no specific drugs are approved that directly target this protein. Complete loss of MBD3 function leads to embryonic lethality in mammals, indicating its central developmental role.

Other names

MBD3 (canonical abbreviation)Methyl-CpG-binding domain protein 3(no prominent alternative symbols; historic context sometimes references Mi-2/NuRD complex subunit—see molecular classification below)

Drugs targeting the NuRD complex, or epigenetic modulators, may regulate gene expression by inhibiting histone deacetylase activity, chromatin remodeling, or altering DNA methylation status; in cancer, altered MBD3 expression can shift transcriptional programs toward or away from tumorigenesis. Modulation of STAT1 transcription (in glioma cells) via altered recruitment of the NuRD complex.